AlphaQuest LLC Raises Stake in Zoetis Inc. $ZTS

Key Points

• AlphaQuest LLC increased its stake in Zoetis Inc. by 54.7% during the first quarter, owning 13,407 shares valued at approximately $2.2 million.
• Zoetis reported $1.76 EPS in its latest quarterly earnings, surpassing estimates of $1.62, with revenues reaching $2.46 billion, a 4.2% increase from the previous year.
• Analysts have mixed views on Zoetis, with four rating the stock as a Buy and four as a Hold, while its consensus price target is $202.43.

AlphaQuest LLC raised its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 54.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,407 shares of the company's stock after purchasing an additional 4,738 shares during the period. AlphaQuest LLC's holdings in Zoetis were worth $2,207,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Mccarter Private Wealth Services LLC increased its position in shares of Zoetis by 6.7% in the 1st quarter. Mccarter Private Wealth Services LLC now owns 3,573 shares of the company's stock valued at $588,000 after purchasing an additional 225 shares during the last quarter. Compound Planning Inc. boosted its holdings in shares of Zoetis by 9.0% in the 1st quarter. Compound Planning Inc. now owns 7,248 shares of the company's stock valued at $1,193,000 after buying an additional 597 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of Zoetis by 5.0% in the 1st quarter. Ameriprise Financial Inc. now owns 3,377,184 shares of the company's stock valued at $556,886,000 after buying an additional 161,431 shares in the last quarter. Norinchukin Bank The boosted its holdings in shares of Zoetis by 36.8% in the 1st quarter. Norinchukin Bank The now owns 290,845 shares of the company's stock valued at $47,888,000 after buying an additional 78,258 shares in the last quarter. Finally, CW Advisors LLC boosted its holdings in shares of Zoetis by 1.3% in the 1st quarter. CW Advisors LLC now owns 85,739 shares of the company's stock valued at $14,113,000 after buying an additional 1,104 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

ZTS traded up $0.7080 during trading on Friday, hitting $156.3180. The stock had a trading volume of 2,426,297 shares, compared to its average volume of 3,450,163. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The firm has a market capitalization of $69.28 billion, a P/E ratio of 26.91, a PEG ratio of 2.51 and a beta of 0.88. The company's 50-day moving average price is $153.84 and its 200 day moving average price is $158.41. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis's revenue was up 4.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ZTS. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Piper Sandler upped their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, UBS Group lowered their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Zoetis has an average rating of "Moderate Buy" and an average target price of $202.43.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president directly owned 15,129 shares of the company's stock, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company's stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.